Rafael Holdings, Inc. is a biotechnology company. The Company holds interests in clinical and early-stage pharmaceutical companies, including a 100% interest in Cyclo Therapeutics, LLC, a biotechnology company focusing on developing its lead clinical candidate, Trappsol Cyclo, which is being evaluated in clinical trials, including an ongoing Phase III trial for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal, and progressive genetic disorder. It also holds an interest in LipoMedix Pharmaceuticals Ltd., a clinical-stage pharmaceutical company; Barer Institute Inc., a wholly owned preclinical cancer metabolism research operation, and an interest in Cornerstone Pharmaceuticals, Inc., a cancer metabolism-based therapeutics company. It holds an interest in Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and a majority interest in Day Three Labs, Inc.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 228.67% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 917.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 917.00K.
Undervalued
The company’s latest PE is -4.03, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.56M shares, decreasing 21.35% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 53.43K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.06.